Equities Analysts Set Expectations for Cencora Q2 Earnings

Cencora, Inc. (NYSE:COR) – Stock analysts at Leerink Partnrs boosted their Q2 2025 earnings per share (EPS) estimates for shares of Cencora in a research report issued on Thursday, January 2nd. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $4.23 per share for the quarter, up from their previous forecast of $4.12. The consensus estimate for Cencora’s current full-year earnings is $14.93 per share. Leerink Partnrs also issued estimates for Cencora’s Q3 2025 earnings at $3.87 EPS, Q4 2025 earnings at $3.84 EPS, FY2025 earnings at $15.39 EPS, FY2026 earnings at $17.11 EPS and FY2028 earnings at $20.75 EPS.

COR has been the topic of a number of other research reports. Barclays increased their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Robert W. Baird lifted their target price on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Wells Fargo & Company reduced their price target on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research report on Friday, December 13th. UBS Group lifted their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $275.60.

Cencora Stock Performance

Shares of COR stock opened at $228.69 on Monday. The company has a market capitalization of $44.20 billion, a P/E ratio of 30.45, a P/E/G ratio of 1.54 and a beta of 0.49. Cencora has a 12-month low of $208.58 and a 12-month high of $253.27. The business’s 50 day moving average is $237.34 and its two-hundred day moving average is $233.53. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Hedge Funds Weigh In On Cencora

Several hedge funds have recently bought and sold shares of COR. Arizona State Retirement System grew its position in shares of Cencora by 6.3% during the second quarter. Arizona State Retirement System now owns 52,047 shares of the company’s stock worth $11,726,000 after buying an additional 3,089 shares in the last quarter. Private Advisor Group LLC lifted its position in shares of Cencora by 11.5% during the 2nd quarter. Private Advisor Group LLC now owns 6,785 shares of the company’s stock worth $1,529,000 after buying an additional 700 shares during the last quarter. Candriam S.C.A. boosted its holdings in shares of Cencora by 21.9% in the 2nd quarter. Candriam S.C.A. now owns 7,897 shares of the company’s stock valued at $1,779,000 after buying an additional 1,420 shares in the last quarter. Savant Capital LLC grew its position in shares of Cencora by 2.1% in the 2nd quarter. Savant Capital LLC now owns 6,511 shares of the company’s stock valued at $1,467,000 after buying an additional 132 shares during the last quarter. Finally, SRS Capital Advisors Inc. increased its position in Cencora by 6.7% during the second quarter. SRS Capital Advisors Inc. now owns 3,338 shares of the company’s stock worth $752,000 after buying an additional 210 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insiders Place Their Bets

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 7.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 94,696 shares of company stock valued at $22,862,734 over the last quarter. 15.80% of the stock is owned by insiders.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.96%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio is presently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.